Comparative informativeness of proteinuria tests in patients with chronic obstructive pulmonary disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the incidence of albuminuria among patients with COPD and assess the informativeness of different proteinuria tests. Material and methods. The study included 200 patients of Krasnodar KCH №2 diagnosed with COPD. The patients were divided into four groups depending on the frequency and severity of exacerbations. All patients were tested for proteinuria using different tests: semi-quantitative «method of dry chemistry», quantification of protein with pyrogallol red, urinary albumin excretion, ß2-MICROGLOBULIN, and protein-creatinine and albumin-creatinine ratios. Results. The semiquantitative method detected proteinuria in 7.5% of patients with COPD, the quantitative method in 15%, the protein-creatinine ratio in 20%, the albumin-creatinine ratio - in 22.5%. Significant inverse correlation was found between the severity of airflow obstruction and urinary excretion of ß2-MICR0GL0BULIN and albumin. Conclusion. The most important marker of early renal dysfunction in patients with COPD is the albumin-creatinine ratio. The highest mean levels of albuminuria, protein-creatinine and albumin-creatinine ratios and the marker of tubular dysfunction ß2-MICR0GL0BULIN WERE OBSERVED IN COPD PATIENTS WITH FREQUENT EXACERBATIONS. THERE WAS A SIGNIFICANT INVERSE CORRELATION BETWEEN THE SEVERITY OF AIRFLOW OBSTRUCTION AND ß2-MICR0GL0BULIN AND albuminuria.

Full Text

Restricted Access

References

  1. Ehteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int. J. Tuberc. Lung. Dis. 2016;20(1):11-23.
  2. Campo G., Pavasini R., Malagu M., Mascetti S., Biscaglia S., Ceconi C., Papi A., Contoli M. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015; 29(2):147-157.
  3. Smith M.C., Wrobel J.P. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2014;9:871-888.
  4. Warnock D.G., Muntner P., McCullough P.A., Zhang X., McClure L.A., Zakai N., Cushman M., Newsome B.B., Kewalramani R., Steffes M.W., Howard G., McClellan W.M.; REGARDS Investigators. Kidney Function, Albuminuria, and All-Cause Mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am. J. Kidney Dis. 2010; 56(5):861-871.
  5. Hemmelgarn B.R., Manns B.J., LloydA., James M.T., Klarenbach S., Quinn R.R., Wiebe N., Tonelli M.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010; 303(5):423-429.
  6. Bulcun E., Ekici M., Ekici A., Kisa U. Microalbuminuria in chronic obstructive pulmonary disease. COPD. 2013;10(2):186-192.
  7. Ford E.S. Urinary Albumin-Creatinine Ratio, Estimated Glomerular Filtration Rate, and All-Cause Mortality Among US Adults With Obstructive Lung Function. Chest. 2015;147(1):56-67.
  8. Федеральные клинические рекомендации по диагностике и лечению ХОБЛ. Российское респираторное общество. 2013. http://www.pulmonology.ru/ download/ C0PD20142.doc
  9. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org
  10. Vart P., Scheven L., Lambers Heerspink H.J., de Jong P.E., de Zeeuw D., Gansevoort R.T.; PREVEND Study Group and the RENAAL Investigators. Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. Am. J. Kidney Dis. 2015;67:70-78.
  11. Raikou V.D. Beta (2)-Microglobulin, Pulse Pressure and Metabolic Alterations in Hemodialysis Patients. URL: http://www.hemodialysis.com/beta-2 microglobulin_pulse pressure and metabolic alterations in hemodialysis patients. html 9.11.12.
  12. Johnston O., Cassidy H., O'Connell S., ORiordan A., Gallagher W., Maguire P.B., Wynne K., Cagney G., Ryan M.P., Conlon P.J., McMorrow T. Identification of beta-2-microglobulin as a urinary biomarker for chronic allograft nephropathy. Proteomics Clin. Appl. 2011;5(7-8):422-431.
  13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. (Suppl.). 2013;3:1-150.
  14. Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Г., Бобкова И.Н., Швецов М.Ю., Цыгин А.Н., Шутов А.М. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефрология. 2012;4:4-26.
  15. Tanaka F., Komi R., Makita S., Onoda T., Tanno K., Ohsawa M., Itai K., Sakata K., Omama S., Yoshida Y., Ogasawara K., Ishibashi Y., Kuribayashi T., Okayama A., Nakamura M.; Iwate-Kenco Study Group. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J. Hypertens. 2016;34(3):506-512.
  16. Jackson C.E., Solomon S.D., Gerstein H.C., Zetterstrand S., Olofsson B., Michelson E.L., Granger C.B., Swedberg K., Pfeffer M.A., Yusuf S., McMurray J.J. CHARM Investigators and Committees. Albuminuria in chronic heartfailure: prevalence and prognostic importance. CHARM Investigators and Committees. Lancet. 2009;374(9689):543-550.
  17. Литвин А. Микроальбуминурия: клиническое значение. Врач. 2011;9: 7-13.
  18. Bulcun E., Ekici M., Ekici A., Kisa U. Microalbuminuria in chronic obstructive pulmonary disease. COPD. 2013;10(2):186-192.
  19. Болотова А.В., Дудникова А.В. Особенности дисфункции почек у пациентов с хронической обструктивной болезнью легких. Клиническая нефрология. 2015;2-3:27-32.
  20. Johnston O., Cassidy H., O'Connell S., ORiordan A., Gallagher W., Maguire P.B., Wynne K., Cagney G., Ryan M.P., Conlon P.J., McMorrow T. Identification of beta-2-microglobulin as a urinary biomarker for chronic allograft nephropathy. Proteomics Clin. Appl. 2011;5(7-8):422-431.
  21. Инюткина Н.В., Шатохина И.С. Определение протеинурии: какой метод выбрать? Справочник заведующего клинико-диагностической лабораторией. 2015;4:33-39.
  22. Usui T. Epidemiology of albuminuria (proteinuria) and its role in clinical trials. Nihon Jinzo Gakkai Shi. 2015;57(8):1275-1280.
  23. Овчаренко С.И. Современный подход к выбору лечения больных хронической обструктивной болезнью легких. Фарматека. 2013;15:64-67

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies